FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy (Q38549680)
Jump to navigation
Jump to search
scientific article published on 17 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy |
scientific article published on 17 July 2015 |
Statements
1 reference
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy (English)
1 reference
Geoffrey Kim
1 reference
Gwynn Ison
1 reference
Amy E McKee
1 reference
Hui Zhang
1 reference
Shenghui Tang
1 reference
Thomas Gwise
1 reference
Rajeshwari Sridhara
1 reference
Eunice Lee
1 reference
Abraham Tzou
1 reference
Reena Philip
1 reference
Haw-Jyh Chiu
1 reference
Tiffany K Ricks
1 reference
Todd Palmby
1 reference
Anne Marie Russell
1 reference
Gaetan Ladouceur
1 reference
Elimika Pfuma
1 reference
Hongshan Li
1 reference
Liang Zhao
1 reference
Qi Liu
1 reference
Rajesh Venugopal
1 reference
Amna Ibrahim
1 reference
Richard Pazdur
1 reference
17 July 2015
1 reference
1 reference
21
1 reference
19
1 reference
4257-4261
1 reference
Identifiers
1 reference
1 reference